Glyn N. Stacey – författare

Medicines from Animal Cell Culture focuses on the use of animal cell culture, which has been used to produce human and veterinary vaccines, interferon, monoclonal antibodies and genetically engineered products such as tPA and erythropoietin. It also addresses the recent dramatic expansion in cell-based therapies, including the use of live cells for tissue regeneration and the culture of stem cells. Medicines from Animal Cell Culture: Provides comprehensive descriptions of methods for cell culture and nutrition as well as the technologies for the preservation and characterisation of both the cells and the derived productsDescribes the preparation of stem cells and others for use in cell-based therapies – an area of burgeoning researchIncludes experimental examples to indicate expected resultsCovers regulatory issues from the UK, the EU and the USA and reviews how these are developing around the worldAddresses the key issues of standardisation and validation with chapters on GLP and GMP for cell culture processesDelivering insight into the exciting world of biological medicines and directions for further investigation into specific topics, Medicines from Animal Cell Culture is an essential resource for researchers and technicians at all levels using cell culture within the pharmaceutical, biotechnology and biomedical industries. It is of value to laboratory managers in these industries and to all those interested in this topic alike.

This book focuses on the current developments and future perspectives on cell therapies. It includes chapters on new scientific developments, non-scientific challenges, standards development and brief summaries of the state of regulation in certain areas. Taken with its companion volume Advanced Cell Therapies: Experiences on the pathway, these two volumes provide perspectives from other professionals focused on supporting successful delivery of safe and effective cell therapy products including regulators, standards organisations and suppliers of raw materials and consulting services. It will draw authors from both North America, Europe and Asia and International organisations to provide a balance of approaches from different jurisdictions. The financial and legal realities of delivering such products will also be addressed by expert authors in the field. The ethical challenges in different parts of the world and for international translation of particular products will also be explored, with specifics provided. Cell Therapy: Current Developments and Future Directions and its companion volume are essential reading for researchers moving into translational science, industry and legal personnel wishing to understand cell therapies, regulators and policy makers developing regulation and guidelines, and advanced students researching this field.